Chronic wound management is a developing market characterized by insufficient technological solutions.
Procedures for excision or destruction of lesion or skin and subcutaneous tissue totaled over 1.3 million in the United States during 1996. Of these about 410, 000 were procedures for debridement of wound, infection or burn. Burns and chronic wound treatment is a market with a 5% annual growth rate.
Technology
EnzySurge provides innovative solutions for chronic wound management. Based on its patented Continuous Streaming Therapy™ (CST) and a series of optimized therapeutic solutions, the Company's DermaStream™ product line delivers effective, affordable, and user-friendly care throughout all phases of wound treatment: wound debridement (removal of necrotic tissue), bacterial load reduction and enhanced healing. DermaStream was designed for use in hospitals, clinics and at home.
EnzySurge combines a patented medical device with pioneering bio-technology research to deliver improved quality of life to chronic-wound patients, via enhanced healing and reduced treatment costs.
Advantages of the EnzySurge solution:
- Eliminates/minimizes surgical intervention and anesthetic injections in the treatment of skin disorders
- Minimizes hospitalizations
- Minimizes scar formation
- Shortens treatment period due to greater efficiency in the use of enzymes
The company's technology is fully covered by patents.
Team
- Amir Shiner, CEO
- Prof. Amihai Freeman, founder, a veteran researcher in the Tel Aviv University Biotechnology Department
- Boaz Gruener, director of marketing and business development
Medical Devices